Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES.

Oncogene. 2009 Apr 16;28(15):1812-20. doi: 10.1038/onc.2009.13. Epub 2009 Mar 16.

2.

Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A.

Anticancer Res. 2010 Apr;30(4):1279-85.

3.

Association between CCND1 G/A870 polymorphism, allele-specific amplification, cyclin D1 expression, and survival in esophageal and lung carcinoma.

Gupta VK, Feber A, Xi L, Pennathur A, Wu M, Luketich JD, Godfrey TE.

Clin Cancer Res. 2008 Dec 1;14(23):7804-12. doi: 10.1158/1078-0432.CCR-08-0744.

4.

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, Tindall EA, Wang Y, Burd CJ, Groh EM, Hoang HN, Giles GG, Severi G, Hayes VM, Henderson BE, Le Marchand L, Kolonel LN, Haiman CA, Baffa R, Gomella LG, Knudsen ES, Rui H, Henshall SM, Sutherland RL, Knudsen KE.

Clin Cancer Res. 2009 Sep 1;15(17):5338-49. doi: 10.1158/1078-0432.CCR-08-2865. Epub 2009 Aug 25.

5.

Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.

Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2190-5. Epub 2006 Feb 6.

6.

Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene.

Olshavsky NA, Comstock CE, Schiewer MJ, Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM, Knudsen KE.

Cancer Res. 2010 May 15;70(10):3975-84. doi: 10.1158/0008-5472.CAN-09-3468. Epub 2010 May 11.

7.

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

Li R, An SJ, Chen ZH, Zhang GC, Zhu JQ, Nie Q, Xie Z, Guo AL, Mok TS, Wu YL.

Hum Pathol. 2008 Dec;39(12):1792-801. doi: 10.1016/j.humpath.2008.05.008. Epub 2008 Aug 19.

PMID:
18715616
8.

Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Paronetto MP, Cappellari M, Busà R, Pedrotti S, Vitali R, Comstock C, Hyslop T, Knudsen KE, Sette C.

Cancer Res. 2010 Jan 1;70(1):229-39. doi: 10.1158/0008-5472.CAN-09-2788. Epub 2009 Dec 22.

9.
10.

Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population.

Zeng Z, Tu J, Cheng J, Yao M, Wu Y, Huang X, Xie X, Zhang X, Lu F, Chen X.

Tumour Biol. 2015 Sep;36(9):6891-900. doi: 10.1007/s13277-015-3401-7. Epub 2015 Apr 8.

11.

Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer.

Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, Dutertre M.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6004-9. doi: 10.1073/pnas.0710748105. Epub 2008 Apr 14.

12.

Cyclin D1b splice variant promotes αvβ3-mediated adhesion and invasive migration of breast cancer cells.

Wu FH, Luo LQ, Liu Y, Zhan QX, Luo C, Luo J, Zhang GM, Feng ZH.

Cancer Lett. 2014 Dec 1;355(1):159-67. doi: 10.1016/j.canlet.2014.08.044. Epub 2014 Sep 1.

PMID:
25193465
13.

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES.

J Biol Chem. 2003 Aug 8;278(32):30339-47. Epub 2003 May 12. Erratum in: J Biol Chem. 2004 Jul 16;279(29):30914.

14.

Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.

Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge Ø, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O.

Br J Cancer. 2012 Nov 6;107(10):1684-91. doi: 10.1038/bjc.2012.463. Epub 2012 Oct 25.

15.

Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).

Rojas P, Benavides F, Blando J, Perez C, Cardenas K, Richie E, Knudsen ES, Johnson DG, Senderowicz AM, Rodriguez-Puebla ML, Conti CJ.

Mol Carcinog. 2009 Jun;48(6):508-16. doi: 10.1002/mc.20489.

16.

Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, Howell A, Dowsett M, Landberg G; TransATAC investigators.

Breast Cancer Res. 2012 Apr 4;14(2):R57.

17.
18.

Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.

Kim CJ, Nishi K, Isono T, Okuyama Y, Tambe Y, Okada Y, Inoue H.

Mol Carcinog. 2009 Oct;48(10):953-64. doi: 10.1002/mc.20547.

PMID:
19415719
19.

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.

Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES.

Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170.

20.

Supplemental Content

Support Center